Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin in Parkinson's Disease Tremor
NCT02419313Phase 2Completed
- Sponsor
- Yale University
- Start
- Aug 2012
- Primary completion
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in Parkinson's disease (PD), sponsored by Yale University. Started Aug 2012; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02419313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419313.